Indaptus Therapeutics, Inc. (INDP)

Price, with every insider trade on it

Closing prices, 12 months · point at a dot for who traded, or at the line for the close

2.51 on 9 Oct 2026

0 buys0 sales at will0 planned sales

Fiscal year 2025, ended 31 Dec 2025, as filed

Net income

$20.85M

Free cash flow

$14.82M

Return on equity

-661.5%

Return on capital

-497.2%

Fiscal years, as filed with the SEC · point at a year for the detail

RevenueNet incomeLoss

From Form 4, most recent first

Date	Insider	Type	Value	Of own stake
14 Aug 2023	Anderson Glen R. 10% owner	Bought	$56.01K	2.1%
11 Aug 2023	Anderson Glen R. 10% owner	Bought	$74.34K	3.1%
10 Aug 2023	Anderson Glen R. 10% owner	Bought	$86.05K	4.1%
1 Dec 2022	Litchev Boyan Vesselinov Chief Medical Officer	Bought	$935.45	76.9%
22 Nov 2022	Litchev Boyan Vesselinov Chief Medical Officer	Bought	$915.00	333%
21 Nov 2022	Meckler Jeffrey A CEO and Director	Bought	$18.24K	14.6%

25out of 100

Profitability 0

Financial strength 35

Growth n/a

Insiders 50

Strongest on insiders (50), weakest on profitability (0). A score of the business, not of the price.

Last 12 months

Only here

Bought

$0.00

0 buys, 0 buyers

Sold

$0.00

0 sales

Planned sales

n/a

under a 10b5-1 plan